Comparative Safety, Bioavailability, and Pharmacokinetics of Oral Dexamethasone, 4-mg and 20-mg Tablets, in Healthy Volunteers Under Fasting and Fed Conditions: A Randomized Open-label, 3-way Crossover Study-Reference-Cited by-同舟云学术

Comparative Safety, Bioavailability, and Pharmacokinetics of Oral Dexamethasone, 4-mg and 20-mg Tablets, in Healthy Volunteers Under Fasting and Fed Conditions: A Randomized Open-label, 3-way Crossover Study

Published:2020-11 Issue:11 Volume:20 Page:768-773
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Bashir Qaiser,Acosta Mark

Funder

Dexcel Pharma Technologies Ltd

Acrotech Biopharma

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference9 articles.

1. Multiple myeloma;Palumbo;N Engl J Med,2011

2. Multiple myeloma;Raab;Lancet,2009

3. Treatment of relapsed and refractory multiple myeloma;Sonneveld;Haematologica,2016

4. Primary dexamethasone treatment of multiple myeloma;Alexanian;Blood,1992

5. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients;Berenson;Blood,2002

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioequivalence evaluation of dexamethasone palmitate injections by intravenous injection in healthy Chinese volunteers: A 2-period crossover trial;2024-06-20

2. Challenges in chemotherapy induced nausea and vomiting (CINV) management: A systematic review;Tropical Journal of Pharmaceutical Research;2024-04-14

3. Population pharmacokinetics of dexamethasone in critically ill COVID-19 patients: Does inflammation play a role?;Journal of Critical Care;2023-12

4. 3D printed matrix solid forms: Can the drug solubility and dose customisation affect their controlled release behaviour?;International Journal of Pharmaceutics: X;2023-12

5. Pharmacokinetic Study of Intranasal Dexamethasone and Methylprednisolone Compared with Intravenous Administration: Two Open-Label, Single-Dose, Two-Period, Two-Sequence, Cross-Over Study in Healthy Volunteers;Pharmaceutics;2022-12-28